Charles Schwab
OREX

Charles Schwab’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Charles Schwab’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-3,275
Closed -$15K – 3114
2016
Q2 		$15K Sell
3,275
-15,119
-82% -$68.4K ﹤0.01% 3095
2016
Q1 		$104K Sell
18,394
-16,912
-48% -$220K ﹤0.01% 2988
2015
Q4 		$608K Buy
35,306
+944
+3% +$22.5K ﹤0.01% 2559
2015
Q3 		$726K Sell
34,362
-11,279
-25% -$387K ﹤0.01% 2494
2015
Q2 		$2.26M Buy
45,641
+10,783
+31% +$645K ﹤0.01% 2012
2015
Q1 		$2.73M Buy
34,858
+1,639
+5% +$102K ﹤0.01% 1889
2014
Q4 		$2.01M Sell
33,219
-2,213
-6% -$111K ﹤0.01% 2009
2014
Q3 		$1.51M Buy
35,432
+9,540
+37% +$512K ﹤0.01% 2116
2014
Q2 		$1.6M Buy
25,892
+1,877
+8% +$109K ﹤0.01% 2095
2014
Q1 		$1.56M Buy
24,015
+2,001
+9% +$135K ﹤0.01% 2065
2013
Q4 		$1.24M Buy
22,014
+1,947
+10% +$109K ﹤0.01% 2170
2013
Q3 		$1.26M Buy
20,067
+1,885
+10% +$128K ﹤0.01% 2101
2013
Q2 		$1.1M Buy
+18,182
New +$1.12M ﹤0.01% 2107

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Charles Schwab's OREX Position: Q3 2016 in Review

Charles Schwab sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2016, closing a stake of 3,275 shares — an estimated $15K sold.

Charles Schwab first reported a position in OREX in Q2 2013 and held it in 13 quarters. The position peaked at $2.73M in Q1 2015. 55 funds tracked by Wall St. Rank hold OREX as of Q3 2016.

  • Charles Schwab reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Charles Schwab sold 3,275 Orexigen Therapeutics, Inc. shares in Q3 2016, an estimated $15K.
  • Charles Schwab first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 13 quarters.
  • Charles Schwab's Orexigen Therapeutics, Inc. position peaked at $2.73M in Q1 2015.
  • 55 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2016.

Based on Charles Schwab's 13F filing for Q3 2016, filed 14 Nov 2016.